ArticleAsian Pacific journal of cancer prevention : APJCP2026
Selective Inhibition of VEGFR2 in Preference to Other Receptor Tyrosine Kinases by Diosgenin, a Natural Steroidal Sapogenin.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the ability of diosgenin and its derivatives to suppress three angiogenic receptor tyrosine kinases-VEGFR2, FGFR1, and PDGFRA-through comprehensive in silico screening, molecular docking, and molecular dynamics simulations.
methodsWe screened 1,525 plant-derived compounds, 20 sapogenins, and three diosgenin derivatives for drug-likeness and bioavailability using SwissADME. The top candidates were docked against the three receptor tyrosine kinases using PyRx. Diosgenin and 14 of its derivatives were then further analyzed. Molecular dynamics simulations were performed using NAMD3 with CHARMM force fields to assess the stability of the protein-ligand complexes. Parameters such as RMSD, RMSF, Rg, and ΔG were evaluated.
resultsDiosgenin was among the top 10 hits for all three receptor tyrosine kinases. It showed the strongest binding and stable interactions with VEGFR2 (ΔG: -11.03 kcal/mol) compared to lenvatinib (ΔG: -7.52 kcal/mol) and sorafenib (ΔG: -4.01 kcal/mol). The FGFR1-diosgenin and PDGFRA-Diosgenin complexes displayed positive ΔG values, indicating less favorable thermodynamic binding. Three diosgenin derivatives (Formosanin C, Dioscin, and 2-Amin-5-(4-pyridyl)-1,3,4-thiadiazole DG-8d moiety) were also evaluated for their anticancer potential. While Formosanin C showed the highest binding affinities among all three derivatives, diosgenin uniquely interacted with the key catalytic residues of VEGFR2, suggesting functionally more relevant inhibition despite slightly lower docking scores. Similarly, Yamogenin, another sapogenin evaluated, exhibited a high binding affinity across all three angiogenic receptors. Although Yamogenin showed high affinity across all three receptors, molecular dynamics confirmed the superior stability of diosgenin with VEGFR2 (ΔG = -11.03 vs. -9.85 kcal/mol).
conclusionDiosgenin represents a promising and selective VEGFR2 inhibitor with potential to have anti-angiogenic therapeutic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.